- Home
- OMH vs RNTX Comparison
OMH vs RNTX Comparison
Compare OMH & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMH
- RNTX
- Stock Information
- Founded
- OMH 2015
- RNTX 2001
- Country
- OMH Singapore
- RNTX United States
- Employees
- OMH N/A
- RNTX N/A
- Industry
- OMH Real Estate
- RNTX Biotechnology: Pharmaceutical Preparations
- Sector
- OMH Finance
- RNTX Health Care
- Exchange
- OMH Nasdaq
- RNTX Nasdaq
- Market Cap
- OMH 35.8M
- RNTX 40.3M
- IPO Year
- OMH 2023
- RNTX N/A
- Fundamental
- Price
- OMH $1.39
- RNTX $1.37
- Analyst Decision
- OMH Hold
- RNTX
- Analyst Count
- OMH 1
- RNTX 0
- Target Price
- OMH N/A
- RNTX N/A
- AVG Volume (30 Days)
- OMH 123.8K
- RNTX 37.6K
- Earning Date
- OMH 07-25-2025
- RNTX 08-13-2025
- Dividend Yield
- OMH N/A
- RNTX N/A
- EPS Growth
- OMH N/A
- RNTX N/A
- EPS
- OMH N/A
- RNTX N/A
- Revenue
- OMH $7,976,578.00
- RNTX N/A
- Revenue This Year
- OMH $28.40
- RNTX N/A
- Revenue Next Year
- OMH $23.07
- RNTX N/A
- P/E Ratio
- OMH N/A
- RNTX N/A
- Revenue Growth
- OMH 117.53
- RNTX N/A
- 52 Week Low
- OMH $0.59
- RNTX $1.33
- 52 Week High
- OMH $6.20
- RNTX $4.40
- Technical
- Relative Strength Index (RSI)
- OMH 45.79
- RNTX N/A
- Support Level
- OMH $1.37
- RNTX N/A
- Resistance Level
- OMH $1.51
- RNTX N/A
- Average True Range (ATR)
- OMH 0.10
- RNTX 0.00
- MACD
- OMH 0.02
- RNTX 0.00
- Stochastic Oscillator
- OMH 45.85
- RNTX 0.00
About OMH Ohmyhome Limited
Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, property management services, and revenue from emerging and other services.
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.